60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60P is a client of RedChip. Visit www.redchip.com/stocks/sxtp to learn more.

Venu Holding Corporation (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery, Roth’s Seafood and Chophouse, and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.

Venu Holding Corp. (VENU) is a client of RedChip Companies, Inc. VENU agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in January 2025, and 10,000 shares of VENU Rule 144 stock, for six months of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. VENU also agreed to pay RedChip a $90,000 fee for a four-week national TV ad campaign aired weekdays from January 13 to February 7, 2025.

Read our full disclosures at: www.redchip.com/legal/disclosures

ASP Isotopes (Nasdaq: ASPI) is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.

ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock, deemed earned immediately after the IPO, beginning in August 2022, for 12 months of RedChip investor awareness services. ASPI also agreed to pay RedChip a $50,000 fee for a national TV ad campaign aired May 10 to May 24, 2024. As of September 2024, RedChip’s shares of ASPI are unrestricted and RedChip intends to sell all of its shares immediately and you may be buying as RedChip is selling. As of November 1, 2024, RedChip has sold all of its ASPI shares.

Read our full disclosures at: www.redchip.com/legal/disclosures

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.

Enlivex Therapeutics (ENLV) is a client of RedChip Companies, Inc. ENLV agreed to pay RedChip Companies, Inc. an $8,000 monthly cash fee, beginning in February 2024, plus 25,000 warrants with an exercise price of $3.25 and 25,000 warrants with an exercise price of $4.25, for six month of investor awareness services. All warrants have a term of three years from date of issuance. ENLV also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired September 11 to September 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired October 14 to October 25, 2024, and a one-time $37,500 fee for a national TV ad campaign aired December 4 to December 17, 2024.

Read our full disclosures at: www.redchip.com/legal/disclosures

Gorilla Technology Group (Nasdaq: GRRR) is a global leader in AI-based IIOT (Industrial Internet of Things) solutions with a strong emphasis on security convergence, video analytics, and big data. Leveraging over 22 years of innovation and industry expertise, Gorilla provides transformative solutions that enhance the safety, efficiency, and operational capabilities of smart cities, smart ports, smart buildings, and more. The company's proprietary technologies empower clients across both public and private sectors by offering predictive insights and robust network defense, driving the next wave of digital transformation. With a footprint spanning over seven countries and 29 granted patents globally, Gorilla Technology is well positioned to accelerate revenue growth as it creates secure, intelligent environments that address the complexities of modern urban life and industrial operations.

Gorilla Technology (GRRR) is a client of RedChip Companies, Inc. GRRR agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in August 2024, and can earn up to 15,000 shares of Rule 144 stock, for six month of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. GRRR also paid RedChip a one-time cash fee of fifty-thousand dollars for a 10-day national TV ad campaign aired October 16-29, 2024.

Read our full disclosures at: www.redchip.com/legal/disclosures

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP.

OKYO Pharma (OKYO) is a client of RedChip Companies, Inc. OKYO agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in August 2024, and 50,000 stock options with a $1 strike price and five-year expiration, for six month of investor awareness services. RedChip intends to and will, if possible, exercise and sell all of its options immediately upon eligibility, and you may be buying as RedChip is selling. OKYO also agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired June 11 through June 25, 2024, a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired August 5 through August 9, 2024, a one-time thirty-eight-thousand five-hundred dollar fee for a 10-day national TV ad campaign aired October 16 through October 29, 2024, and a one-time #33,000 cash fee for a 10-day national TV ad campaign aired November 7 through November 20, 2024.

Read our full disclosures at: www.redchip.com/legal/disclosures

VSee Health is a software-as-a-service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. VSee Health's system allows a telehealth mobile app to be created or a telehealth system to be integrated into existing hospital operations in days. With a focus on patient disease state telemedicine and turnkey billing services, VSee Health has integrated an intensive care, critical care and neuro solution, powered by iDoc Telehealth Solutions, as its initial module for the VSee Health software platform. This technology encompasses a set of integrated telehealth technologies and a team of neurointensivists, neurologists, and tele-radiologists that treat and coordinate care for acutely ill patients 24/7/365 in the neurointensive care unit (Neuro-ICU), cardiac surgery intensive care unit (CS-ICU) and the intensive care unit (ICU) for stroke, brain trauma and a wide range of neurological conditions.

Visit www.redchip.com/stocks/VSEE to learn more.

VSee Health (VSEE) is a client of RedChip Companies. VSEE agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in October 2024, for six month of investor awareness services. VSEE also agreed to pay RedChip a $50,000 fee for a national TV ad campaign aired weekdays from November 11 to November 22, 2024.

Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of NASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.

Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2024, for four month of investor awareness services. CANF also agreed to pay RedChip one-time cash fees of fifty-thousand dollars, twenty-two thousand five hundred dollars, and forty-five thousand dollars, for two-week national TV ad campaigns aired weekdays from June 3 to June 14, 2024, June 19 to June 25, 2024, and October 2 to October 15, 2024, respectively.

For full disclosure, visit RedChip.com/disclosures

The MUSQ Global Music Industry ETF (MUSQ) offers investors focused exposure to the growing global music industry. The fund aims to replicate the performance of the MUSQ Global Music Industry Index (MUSQIX), which rebalances quarterly and includes publicly traded companies and royalty funds with significant revenues tied to music. MUSQ provides access to key segments such as music streaming, live events and ticketing, content distribution, satellite and broadcast radio, and music equipment and technology. Launched in July 2023, the fund is positioned to benefit from the evolving digital landscape, including the rise of streaming and AI-driven content creation.

Visit RedChip.com to learn more.

MUSQ is a client of RedChip Companies, Inc. MUSQ agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in August 2024, for three month of investor awareness services. MUSQ also agreed to pay RedChip a one-time $20,000 fee for a national TV ad campaign aired weekdays from October 4 to October 15, 2024, and a one-time $20,000 cash fee for a national TV ad campaign aired weekdays from November 1 to November 14, 2024.

For full disclosure, visit RedChip.com/disclosures

Calidi Biotherapeutics (NYSE American:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

Calidi Biotherapeutics (CLDI) is a client of RedChip Companies, Inc. CLDI agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in March 2024, and 25,000 shares of Rule 144 stock for 6 months of investor awareness services. CLDI also agreed to pay RedChip a one-time $40,000 fee for a national TV ad campaign aired weekdays from April 3 to April 17, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from May 28 to June 11, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from July 7 to August 2, 2024, a one-time $20,000 fee for a national TV ad campaign aired weekdays from August 5 to August 9, 2024, and a one-time $20,000 fee for a national TV ad campaign aired weekdays from October 16 to October 24, 2024.

For full disclosure, visit RedChip.com/disclosures